EDITOR'S PICKS

12
上一页 下一页
More>>
LATEST MOST VIEWED: LAST ONE YEAR MOST VIEWED: LAST TWO YEARS MOST DOWNLOADED
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

    Agnese C. Pippione , Donatella Boschi , Klaus Pors , Simonetta Oliaro-Bosso , Marco L. Lolli

    Androgens play an important role in prostate cancer (PCa) development and progression. Although androgen deprivation therapy remains the front-line treatment for advanced prostate cancer, patients eventually relapse with the lethal form of the disease. The prostate tumor microenvironment is... Read more

    J Cancer Metastasis Treat 2017;3:328-61. | doi:10.20517/2394-4722.2017.44
    Published on: 12 Dec 2017  | Viewed:0  | Downloaded:0
    +HTML| PDF
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting

    Robert A. Falconer , Paul M. Loadman

    The membrane-type matrix metalloproteinases (MT-MMPs), an important subgroup of the wider MMP family, demonstrate widespread expression in multiple tumor types, and play key roles in cancer growth, migration, invasion and metastasis. Despite a large body of published research, relatively little... Read more

    J Cancer Metastasis Treat 2017;3:315-27. | doi:10.20517/2394-4722.2017.40
    Published on: 12 Dec 2017  | Viewed:0  | Downloaded:0
    +HTML| PDF
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    Tumor heterogeneity and therapy resistance - implications for future treatments of prostate cancer

    Fiona M. Frame , Amanda R. Noble , Sandra Klein , Hannah F. Walker , Rakesh Suman , Richard Kasprowicz , Vin M. Mann , Matt S. Simms , Norman J. Maitland

    Aim: To develop new therapies for prostate cancer, disease heterogeneity must be addressed. This includes patient variation, multi-focal disease, cellular heterogeneity, genomic changes and epigenetic modification. This requires more representative models to be used in more innovative ways.... Read more

    J Cancer Metastasis Treat 2017;3:302-14. | doi:10.20517/2394-4722.2017.34
    Published on: 6 Dec 2017  | Viewed:220  | Downloaded:9
    +HTML| PDF
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    Prostate cancer exosomes as modulators of the tumor microenvironment

    Alex P. Shephard , Vincent Yeung , Aled Clayton , Jason P. Webber

    Researchers are currently trying to understand why some men with prostate cancer go on to develop aggressive disease whilst others maintain slow growing tumors. Although endogenous genetic anomalies within the tumor cell are important, the prevailing view is that the tissue microenvironment as a... Read more

    J Cancer Metastasis Treat 2017;3:288-301. | doi:10.20517/2394-4722.2017.32
    Published on: 6 Dec 2017  | Viewed:191  | Downloaded:13
    +HTML| PDF
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    HOX transcription factors and the prostate tumor microenvironment

    Richard Morgan , Hardev S. Pandha

    It is now well established that the tumor microenvironment plays an essential role in the survival, growth, invasion, and spread of cancer through the regulation of angiogenesis and localized immune responses. This review examines the role of the HOX genes, which encode a family of... Read more

    J Cancer Metastasis Treat 2017;3:278-87. | doi:10.20517/2394-4722.2017.31
    Published on: 6 Dec 2017  | Viewed:63  | Downloaded:4
    +HTML| PDF
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    Getting better at treating prostate cancer: what clinicians should want from scientists

    Malcolm Mason

    If the treatment landscape for prostate cancer is to be transformed, clinicians and scientists must work together ever more closely. Prostate cancer defeats physicians when patients are not accurately stratified according to patients’ risk of dying of disease, when the effects of tumor... Read more

    J Cancer Metastasis Treat 2017;3:271-7. | doi:10.20517/2394-4722.2017.51
    Published on: 17 Nov 2017  | Viewed:553  | Downloaded:16
    +HTML| PDF
  • image
    Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?| Open Access

    Getting closer to prostate cancer in patients - what scientists should want from clinicians

    Norman J. Maitland

    For scientists pursuing drug development for prostate cancer, it is critical that an appropriate ex vivo or in vitro model system is available for study. Cancer research has generally consisted of: (1) finding the means to arrest fast growing cancer cells; or (2) (as a compromise) to slow down... Read more

    J Cancer Metastasis Treat 2017;3:262-70. | doi:10.20517/2394-4722.2017.23
    Published on: 17 Nov 2017  | Viewed:290  | Downloaded:17
    +HTML| PDF
  • image
    Topic: Cancer Immunotherapy| Open Access

    Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

    Stanley J. Oiseth , Mohamed S. Aziz

    The knowledge that the body possesses natural defenses to combat cancer existed long before the modern period, with multiple anecdotal reports of tumors miraculously disappearing, sometimes spontaneously or after a febrile or infectious episode. Spontaneous tumor regression of untreated malignant... Read more

    J Cancer Metastasis Treat 2017;3:250-61. | doi:10.20517/2394-4722.2017.41
    Published on: 31 Oct 2017  | Viewed:1787  | Downloaded:894
    +HTML| PDF
  • image
    Topic: Cancer Immunotherapy| Open Access

    Cell-mediated immunotherapy for hepatocellular carcinoma

    Wei-Chen Lee

    Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most of the time, these tumors are diagnosed at late stages. Because no effective treatments exist for patients with advanced stage HCC, there is an urgent need for novel, effective treatments. Cancer cells originate as a... Read more

    J Cancer Metastasis Treat 2017;3:244-9. | doi:10.20517/2394-4722.2017.48
    Published on: 31 Oct 2017  | Viewed:252  | Downloaded:22
    +HTML| PDF
  • image
    Topic: Cancer Immunotherapy| Open Access

    Immunological aspect of the liver and metastatic uveal melanoma

    Mizue Terai , Michael J. Mastrangleo , Takami Sato

    Uveal (eye) melanoma is the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients is generally short and... Read more

    J Cancer Metastasis Treat 2017;3:231-43. | doi:10.20517/2394-4722.2017.39
    Published on: 31 Oct 2017  | Viewed:336  | Downloaded:32
    +HTML| PDF
+MoreView all articles
Subscribe

To receive email updates about the journal, please subscribe here.

Partners
News More>>
Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Partners
Copyright © 2017 OAE Publishing Inc. All Rights Reserved.